Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

R J LiesnerM AbashidzeO AleinikovaC AltisentM J BelletruttiA Borel-DerlonManuel D CarcaoH ChambostA K C ChanL DubeyJ DucoreN A FouziaM GattensY GruelB GuilletN KavardakovaM El KhorassaniA KlukowskaT LambertS LohadeM SigaudV TureaJ K M WuV VdovinA PavlovaM JansenL BelyanskayaO WalterS KnaubE J Neufeld

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2017)

These interim data show a cumulative incidence of 12.8% for HT inhibitors and convincing efficacy and tolerability in PUPs treated with Nuwiq® .

Keyphrases

endothelial cells
risk factors
open label
early onset
induced pluripotent stem cells
clinical trial
drug induced
newly diagnosed
data analysis
study protocol